Want to see ASMB full AI Analyst Report?
ASMB Stock Chart & Stats
$35.33
$0.60(2.35%)
At close: 4:00 PM EDT
$35.33
$0.60(2.35%)
Day’s Range― - ―
52-Week Range$20.23 - $39.71
Previous CloseN/A
Volume1.34K
Average Volume (3M)230.18K
Market Cap
$716.29M
Enterprise Value$200.09
Total Cash (Recent Filing)$320.36M
Total Debt (Recent Filing)$2.35M
Price to Earnings (P/E)66.8
Beta1.26
Next Earnings
Nov 11, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.55
Shares Outstanding20,360,596
10 Day Avg. Volume321,346
30 Day Avg. Volume230,182
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$49.50Price Target Upside40.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$52.01M
Bulls Say, Bears Say
Bulls Say
Strong Capitalization And Low LeverageMinimal debt relative to the equity base limits financing risk and preserves flexibility to fund clinical programs. The expanded asset and equity base gives Assembly greater resilience while it advances development without substantial debt-service constraints.
Broader ABI-6250 Pipeline OpportunityExtending ABI-6250 across multiple serious liver diseases increases the program’s commercial and development optionality. The targeted indications have limited treatment options, while planned Phase 2 studies provide defined catalysts for validating the platform.
Substantial Funding For Clinical DevelopmentThe sizable capital raise strengthens Assembly’s ability to execute its clinical strategy and reduces near-term dependence on additional financing. Participation from healthcare-focused investors, including Gilead Sciences, also supports access to development capital.
Bears Say
Persistent Operating And Free Cash OutflowsAssembly remains dependent on external capital because research and clinical operations consume substantial cash. Although the burn improved from earlier periods, negative operating and free cash flow means the business is not yet self-funding.
No Commercial Product RevenueWithout an approved commercial product, recurring revenue remains uncertain and depends on collaboration payments, milestones or future royalties. This leaves financial performance exposed to development outcomes and continued access to external financing.
Operating Profitability Remains UnprovenNear-breakeven net income has not yet translated into sustainable operating profitability. Negative EBIT and EBITDA, combined with volatile results, make long-term earnings difficult to forecast and increase dependence on successful pipeline progression.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $20.23 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $716.29M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 69 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.724 by $0.524.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.66.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 20,360,596 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.724. Following the earnings report the stock price went up 10.017%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.50 (40.11% Upside)
$49.50 (40.11% Upside)
Blogger Sentiment
Bullish
ASMB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 376.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $674.3 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 22.2%
Last 30 Days ▲ 22.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
309.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$49.50
▲(40.11% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
26.40% Insiders
3.69% Mutual Funds
63.30% Other Institutional Investors
1.30% Public Companies and
Individual Investors